Ignite Creation Date:
2025-12-24 @ 9:43 PM
Ignite Modification Date:
2026-02-23 @ 12:20 PM
Study NCT ID:
NCT06105632
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-16
First Post:
2023-10-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Sponsor:
Pfizer
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced or Metastatic Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Estrogen receptor positive [ER(+)] | View |
| None | Human epidermal growth factor receptor 2 negative [HER(-)] | View |
| None | ER(+)/HER2(-) | View |
| None | Advanced Breast Cancer | View |
| None | Breast tumor | View |
| None | Breast cancer | View |
| None | fulvestrant | View |
| None | everolimus | View |
| None | exemestane | View |
| None | Partial Response+ (PR+) | View |
| None | Metastatic breast cancer | View |
| None | Hormone Therapy | View |
| None | Hormone positive breast cancer | View |
| None | Recurrent breast cancer | View |
| None | HR+ | View |
| None | HER2-negative | View |
| None | Relapse | View |
| None | Recurrent | View |
| None | Second line treatment. | View |